

**ABSTRACT OF THE DISCLOSURE**

Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g. , preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.

Patent No. 6,440,000